Noninvasive Biomarker for Predicting Treatment Response to Concurrent Chemoradiotherapy in Patients with Hepatocellular Carcinoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To investigate noninvasive biomarkers for predicting treatment response in patients with locally advanced HCC who underwent concurrent chemoradiotherapy (CCRTx). Materials and Methods: Thirty patients (55.5 ± 10.2 years old, M:F = 24:6) who underwent CCRTx due to advanced HCC were enrolled. Contrast-enhanced US (CEUS) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) were obtained before and immediately after CCRTx. The third CEUS was obtained at one month after CCRTx was completed. Response was assessed at three months after CCRTx based on RECIST 1.1. Quantitative imaging biomarkers measured with CEUS and MRI were compared between groups. A cutoff value was calculated with ROC analysis. Overall survival (OS) was compared by the Breslow method. Results: Twenty-five patients were categorized into the non-progression group and five patients were categorized into the progression group. Peak enhancement of the first CEUS before CCRTx (PE1) was significantly lower in the non-progression group (median, 18.6%; IQR, 20.9%) than that in the progression group (median, 59.1%; IQR, 13.5%; P = 0.002). There was no significant difference in other quantitative biomarkers between the two groups. On ROC analysis, with a cutoff value of 42.6% in PE1, the non-progression group was diagnosed with a sensitivity of 90.9% and a specificity of 100%. OS was also significantly longer in patients with PE1 < 42.6% (P = 0.014). Conclusion: Early treatment response and OS could be predicted by PE on CEUS before CCRTx in patients with HCC.
Abstract
Purpose: To investigate noninvasive biomarkers for predicting treatment response in patients with locally advanced HCC who underwent concurrent chemoradiotherapy (CCRTx). Materials and Methods: Thirty patients (55.5 ± 10.2 years old, M:F = 24:6) who underwent CCRTx due to advanced HCC were enrolled. Contrast-enhanced US (CEUS) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) were obtained before and immediately after CCRTx. The third CEUS was obtained at one month after CCRTx was completed. Response was assessed at three months after CCRTx based on RECIST 1.1. Quantitative imaging biomarkers measured with CEUS and MRI were compared between groups. A cutoff value was calculated with ROC analysis. Overall survival (OS) was compared by the Breslow method. Results: Twenty-five patients were categorized into the non-progression group and five patients were categorized into the progression group. Peak enhancement of the first CEUS before CCRTx (PE1) was significantly lower in the non-progression group (median, 18.6%; IQR, 20.9%) than that in the progression group (median, 59.1%; IQR, 13.5%; P = 0.002). There was no significant difference in other quantitative biomarkers between the two groups. On ROC analysis, with a cutoff value of 42.6% in PE1, the non-progression group was diagnosed with a sensitivity of 90.9% and a specificity of 100%. OS was also significantly longer in patients with PE1 < 42.6% (P = 0.014). Conclusion: Early treatment response and OS could be predicted by PE on CEUS before CCRTx in patients with HCC.
참고문헌 (28)
- Johnson PJ, "Non-surgical treatment of hepatocellular carcinoma", HPB (Oxford), 7, pp.50~55 (2005)
- Bruix J, "Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma", Gastroenterology, 150, pp.835~853 (2016)
- Lee HS, "Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy", Ann Surg Oncol, 21, pp.3646~3653 (2014)
- Choi Y, "Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy", J Radiat Res, 55, pp.113~120 (2014)
- Cho IR, "Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B", C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with, Oncotarget, pp.2017, 8[DOI]
- Chong JU, "Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus", Ann Surg Oncol, 25, pp.3308~3315 (2018)
- 한광협, "Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy", Yonsei Medical Journal, 57(5), pp.1276~1281 (2016), 연세대학교의과대학[DOI]
- Jiang T, "Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma", J Hepatol, 58, pp.169~177 (2013)
- Hsu CY, "Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur", uracil, 2011, pp.55, 858~865
- Zhu AX, "Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study", J Clin Oncol, 27, pp.3027~3035 (2009)
- Wang D, "Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplantfree survival during chemoembolization of hepatocellular carcinoma", Radiology, 272, pp.587~597 (2014)
- Liang PC, "Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide", Hepatol Int, 9, pp.258~268 (2015)
- Zhou JH, "Contrastenhanced gray-scale ultrasound for quantitative evaluation of tumor response to chemotherapy: preliminary results with a mouse hepatoma model", AJR Am J Roentgenol, 196, pp.W13~W17 (2011)
- Zhou J, "Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound", Acad Radiol, 17, pp.646~651 (2010)
- Merz M, "Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases", Invest Radiol, 47, pp.422~429 (2012)
- 정용은, "Contrast-enhanced ultrasonography: advance and current status in abdominal imaging", ULTRASONOGRAPHY, 34(1), pp.3~18 (2015), 대한초음파의학회
- Minami Y, "Imaging modalities for assessment of treatment response to nonsurgical hepatocellular carcinoma therapy: contrast-enhanced US, CT, and MRI", Liver Cancer, 4, pp.106~114 (2015)
- Han KH, "Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis", Cancer, 113, pp.995~1003 (2008)
- Kim KA, "Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy", J Magn Reson Imaging, 39, pp.286~292 (2014)
- Korpisalo P, "Ultrasound imaging with bolus delivered contrast agent for the detection of angiogenesis and blood flow irregularities", Am J Physiol Heart Circ Physiol, 307, pp.H1226~H1232 (2014)
- Park HJ, "Radiationinduced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)", Radiat Res, 177, pp.311~327 (2012)
- Rockwell S, "Hypoxia and radiation therapy: past history, ongoing research, and future promise", Curr Mol Med, 9, pp.442~458 (2009)
- Zahra MA, "Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy", Lancet Oncol, 8, pp.63~74 (2007)
- Niizawa G, "Monitoring of hepatocellular carcinoma, following proton radiotherapy, with contrast-enhanced color Doppler ultrasonography", J Gastroenterol, 40, pp.283~290 (2005)
- Thng CH, "Perfusion imaging in liver MRI", Magn Reson Imaging Clin N Am, 22, pp.417~432 (2014)
- Chen BB, "Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma:comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy", Radiology, 281, pp.454~464 (2016)
- Hsu C, "Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study", J Hepatol, 56, pp.1097~1103 (2012)
- Liang PC, "Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma:a preliminary result", Liver Int, 27, pp.516~528 (2007)